Dual Checkpoint Blockade No Help in PD-L1-High NSCLC

(MedPage Today) -- Adding a CTLA-4 checkpoint inhibitor to pembrolizumab (Keytruda) failed to improve survival in previously untreated patients with metastatic non-small cell lung cancer (NSCLC) and high PD-L1 expression levels, a phase III trial...